EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel By Ogkologos - August 26, 2025 157 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Targeting CLDN18.2 with Zolbetuximab Prolongs Survival When Combined with mFOLFOX6 in... April 19, 2023 Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk... June 18, 2025 2023 ASCO Annual Meeting Research Round Up: Improving Symptom Monitoring and... September 21, 2023 FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma January 25, 2021 Load more HOT NEWS What to Expect During Recovery From a Bone Marrow Transplant: An... Cancer in My Community: Providing Free Access to Cancer Care in... Study Shows 4 Drugs Better Than 3 for Women with HER2-Positive... Identification of Potential Biomarkers for Clinical Benefit Following Dual Neoadjuvant Anti-HER2...
